Skip to main content

Table 1 Pretreatment clinical characteristics categorized according to treatment administered to 156 patients with high-risk prostate cancer, adjusted for propensity scores

From: Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis

Pretreatment characteristics Radiation therapy (N = 78) Radical prostatectomy (N = 78) P
Age (year, median) 73.5 71 0.0633a
Initial prostate-specific antigen level (ng/mL, median) 21.42 20.00 0.3886
Clinical T stage    
T1c 19 22 0.8482
T2 23 19
T3 36 37  
Biopsy Gleason score    
≤6 5 4 0.9384
7 24 23
≥8 49 51  
Follow-up period (month, median) 37.6 31.5 0.3338
  1. aP values indicate statistical significance.